Navigation Links
Synthetic Biologics to Present at the 15th Annual Rodman & Renshaw Global Investment Conference in New York City
Date:9/3/2013

ROCKVILLE, Md., Sept. 3, 2013 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE-MKT: SYN), a developer of biologics focused on the prevention and treatment of serious infectious diseases, announced today that Jeffrey Riley, CEO, will present at the 15th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC.  Mr. Riley is scheduled to present at 12:05 p.m. (Eastern Time) on Monday, September 9, 2013 at the Millennium Broadway Hotel in New York City.

A live webcast of Synthetic Biologics' presentation can be accessed by logging onto the internet at http://wsw.com/webcast/rrshq23/SYN. After the presentation, a replay will be archived and accessible for 30 days at the same website.

Mr. Riley, as well as Synthetic Biologics' CFO, C. Evan Ballantyne, will be available to participate in one-on-one meetings with attendees who are registered for the conference. If you are an institutional investor, and would like to attend the Company's presentation, please register for the Rodman & Renshaw conference using the following link www.rodm.com. Once your registration is confirmed, you will be prompted to log into the conference website and may request a one-on-one meeting with the Company.

About Synthetic Biologics, Inc.

Synthetic Biologics, Inc. (NYSE-MKT: SYN) is a biotechnology company focused on the development of biologics for the prevention and treatment of serious infectious diseases. The Company is developing an oral enzyme for the prevention of C. difficile infections, and a series of monoclonal antibody therapies for the treatment of Pertussis and Acinetobacter infections. In addition, the Company is developing a drug candidate for the treatment of relapsing-remitting multiple sclerosis and cognitive dysfunction in multiple sclerosis. For more information, please visit Synthetic Biologics' website at www.syntheticbiologics.com.

To download Synthetic Biologics' investor relations mobile device app, which allows users access to the Company's SEC documents, press releases and events, please click on the following links to download the IRapp on your iPhone and iPad or your Android mobile device.


'/>"/>
SOURCE Synthetic Biologics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Synthetic Biologics Reports Second Quarter 2013 Financial Results and Operational Update
2. Synthetic Biologics to Report Second Quarter 2013 Financial Results
3. Synthetic Biologics Initiates Manufacturing Process for C. difficile Infectious Disease Program
4. Synthetic DNA Deemed Patentable by US Supreme Court, Gene Synthesis and Codon Optimization Provide Potential Pathway to Patentability
5. Synthetic Biologics to Present at OneMedForum New York 2013
6. New England Biolabs supports iGEM synthetic biology competition
7. Synthetic Biologics to Present at the 2nd Annual Marcum LLP MicroCap Conference
8. Intrexon Organizes Around New Synthetic Biology Markets
9. Intrexon Corporation Raises $150 Million for Synthetic Biology Initiatives
10. Synthetic Biologics Reiterates that the Infectious Disease Collaboration with Intrexon Remains in Effect
11. Express Genes by Eurofins MWG Operon Offers 4 Day Delivery of Synthetic Genes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... ... 23, 2017 , ... The Academy of Model Aeronautics (AMA), ... Association (UAA), the unifying voice for collegiate aviation education, are launching a joint ... and success through a STEM-based education platform. , Much like the program currently ...
(Date:6/22/2017)... ... June 21, 2017 , ... RMC Pharmaceutical Solutions, Inc. ... Timothy Reinhardt to manage the new site. , Tim has 25 years of ... most recent role as the Director of Manufacturing and Supplier Quality Assessment. ...
(Date:6/22/2017)... Wendelsheim, Germany (PRWEB) , ... June 22, 2017 ... ... , is taking over the allergy specialists DST Diagnostische Systeme & Technologien GmbH, ... We all know someone who suffers from hay fever, urticaria, asthma, atopic eczema ...
(Date:6/22/2017)... ... June 22, 2017 , ... ... RegMedNet has produced a Spotlight series on “Cell Therapy ... and perspectives by leading experts on the unique regulatory challenges of stem cell ...
Breaking Biology Technology:
(Date:3/29/2017)... CHICAGO , March 29, 2017  higi, the ... ecosystem in North America , today ... Partners and the acquisition of EveryMove. The new investment ... extensive set of tools to transform population health activities ... and lifestyle data. higi collects and secures ...
(Date:3/24/2017)... 24, 2017 Research and Markets has announced ... Analysis & Trends - Industry Forecast to 2025" report to ... The ... a CAGR of around 15.1% over the next decade to reach ... analyzes the market estimates and forecasts for all the given segments ...
(Date:3/22/2017)... Optimove , provider of the ... as 1-800-Flowers and AdoreMe, today announced two new ... Using Optimove,s machine learning algorithms, these features allow ... recommendations to their customers based not just on ... intent drawn from a complex web of data ...
Breaking Biology News(10 mins):